Dave Levitan

A comprehensive genomic analysis of more than a thousand sarcoma patients found that about half had putatively pathogenic variations in either known or novel cancer genes.

An infrared laser-based version of the traditional Chinese medicinal technique known as moxibustion was found to improve cancer-related fatigue.

A small genomic study of patients with chemoradiation-treated urothelial carcinoma of the bladder found similar mutation patterns between primary and recurrent tumors.

In a new practice guideline, the American Society of Clinical Oncology offered recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer.

The combination of pemetrexed and gefitinib offered improved progression-free survival in East Asian patients with advanced nonsquamous NSCLC and activating EGFR mutations.

A study found that follicle-stimulating hormone receptors are expressed in many ovarian tumors, and not in normal ovarian tissue, thus representing a promising therapeutic target.

Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors.

Survivors of fusion-negative sarcomas have a higher risk of developing a second malignant neoplasm than those who had fusion-positive sarcomas.

A novel urine-based DNA test was effective at detecting bladder cancer, and in particular at identifying patients with gross hematuria who do not require cystoscopy.

Outcomes after salvage radiotherapy are affected by variables related to prostatectomy for men with prostate cancer, but its use at lower PSA levels may improve outcomes.

A trial showed that KRAS wild-type NSCLC patients fare better with regimens containing erlotinib, while KRAS-mutated patients had better outcomes without erlotinib.

A phase I trial of selinexor found the drug was reasonably well tolerated and showed some activity in patients with advanced soft-tissue or bone sarcoma with progressive disease.

New NCCN guidelines regarding genomic profiling will likely yield important opportunities to improve the care of patients with advanced bladder cancer.

A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer.

A meta-analysis found that a Mediterranean diet with no limits on fat intake may reduce the incidence of breast cancer, as well as several other outcomes, compared to other diets.

The combination of everolimus and exemestane was deemed generally tolerable with a manageable safety profile in women with advanced HR-positive/HER2-negative breast cancer.

Elevated levels of neopterin were found to be significantly associated with poorer survival outcomes in patients with ovarian cancer.

Both African-American and Caucasian patients with advanced RCC have seen improved survival with targeted therapies, though African-Americans still experience survival disadvantages.

Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.

Zoledronate in combination with chemotherapy failed to improve outcomes over chemotherapy alone in patients with osteosarcoma.

A randomized phase III trial found that a hypofractionated radiotherapy regimen was not superior to, but generally equivalent to a conventional radiotherapy scheme in men with localized prostate cancer.

Two parts of a phase I trial found that nivolumab could be a good first-line treatment option for patients with advanced non–small-cell lung cancer.

A large, prospective analysis showed that risk factors for ovarian cancer demonstrate substantial heterogeneity in their associations with histologic subtypes of the disease.

The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification

Three single-nucleotide polymorphisms were identified that are significantly associated with OS in two separate cohorts of pediatric Ewing sarcoma patients.

A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.

The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.

A database analysis showed that the addition of external beam radiotherapy to ADT significantly improves overall survival in men with metastatic prostate cancer.

A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.

The use of hemithoracic pleural IMRT after chemotherapy could become part of a new lung-sparing therapy in patients with malignant pleural mesothelioma.